TMO - Earnings call transcript Q3 2019 | Thermo Fisher Scientific Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2019 Third Quarter Conference Call. [Operator Instructions]

I would now like to introduce our moderator for the call, Mr. Kenneth Apicerno, Vice President of Investor Relations. Mr. the begin may you call. Apicerno,

Kenneth Apicerno

thank Good joining for morning, and us. you

President is call and our Vice Officer. with the Marc Stephen Chief me Senior Officer; On Executive today Casper, Financial Chief President Williamson, and and

future release note XXXX X, archived the is under of XXXX. of be expectations the A Please and Webcasts earnings and website press of on call copy webcast Investors the is the live of this in Presentations quarter will Investors our website heading our Section and heading our thermofisher.com third being Results. until Financial available the November Section under

important the discussed of ended a including forward-looking before Various for Form Safe the provisions me under our remarks materially So, the Actual purposes briefly also under statement. Exchange XX, may for Harbor with Commission, the Securities Securities indicated which Litigation on filings. the under in report differ SEC may the of we XXXX. in Safe from constitute quarterly make these of and about Harbor those plans let Reform by file statements begin, that statements the results factors, heading expectations, on Act XXXX is as Company’s of available cover we the June Risk quarter Company’s Investor and Factors, section XX-Q result various caption website future is Private our those prospects the forward-looking and

as should today. date obligation on any the to our do forward-looking if we not we While so update to any you our subsequent as statements representing these change, point may elect to rely therefore views statements estimates future, some of forward-looking specifically disclaim at in even

to most GAAP. will reconciliation prepared of financial non-GAAP this be measures or Generally the with these certain during not Also measures A Accepted Accounting Principles we financial call, accordance to in the also future measures the quarter GAAP Investors directly press is and and our Financial earnings of the Information. website our comparable expectations under section XXXX in heading third in referring of available release

will call now I So turn with to Marc. over the that,

Marc Casper

Hello you, effectively joining an achieving to delivered and for our our Thanks performance, continuing Fisher make customers. to another growth for today Ken. our everyone. call. Thermo Thank strategy even stronger for good We great while quarter, execute strong QX morning financial us partner Scientific

we As you press new quarter saw value for another expanded revenue enhance earnings customer unique innovation we in to was and our growth. excellent release, It proposition. and delivered global product capabilities our our active

further returning and capital growth We share also the execute capital on to our customers. with offering completing to carried of the our stock and capitalizing we our opportunities end M&A buybacks markets to continue to and by into our QX had shareholders our strategic strengthening strength We momentum gain through strong deployment continued strategy, dividends.

a highlights morning, performance. have We begin let me of lot with so this to an QX overview financial cover of our

First, growth in $X.XX a per adjusted XX% increase excellent we share. achieving delivered EPS to

$X.XX revenue billion, X% QX to increased Our in year-over-year. growing

the third our XX operating in points adjusted billion quarter. Our increased X% we $X.XX income adjusted to to margin and by basis expanded XX.X% operating

all another by was So quarter it measures, us. for excellent

QX, had market. color market QX delivered serving on strength we double-digit markets. end strong growth. and of conditions with quarter we across this continued growth give be in performance another strong will our we the pharma very I our performance Now, our with delivered starting In end more of of overview In biotech, and all you to an businesses quarter, excellent in

and we growth all market growth by major value productivity. leveraging our so here help our across in end single-digit delivered academic in customers their good continued unique excellent proposition our accelerate QX, geographies. to In our increase innovation government, of pipelines momentum We and and this mid

the customer quarter our this set. the continued business industrially was in applied, and to demand as delivered very QX industrial year growth strong we strong Turning It to due our expected, spectrometry good businesses. in in in from mass was to flat focused and we see here last growth chromatography

diagnostics grew serving QX. in high by and in the immunodiagnostics. in our diagnostics market broad-based saw growth end in single-digits this healthcare, Finally, and transplant we businesses led We

to in in our our successfully is market are results. So that summary, teams growth we and continue strategy, execute strong gaining share reflected clearly our

Continuously strategy, a segue new leveraging impact innovative our of to as delivering proposition more a of in growth That unique three markets a and good know, high the which scale detailed customers. products, our and discussion value our elements. is developing consists you growth emerging to high

and great these each make to some cover will continue progress then of of in QX We I highlights. areas in the

focused of our terms we are from investments. in significant leading on new product value innovation, creating R&D First,

We the committed on customers to continuously advance are ease their work helping of bar by our and accuracy speed, use. raising

early and quarter QX kicked innovation August. it industry a was major two a for another in we productive strong with conferences showing off

new First, Chemistry, instruments for that launched for ultimately better for clinicians Clinical laboratory analytical at diagnostic Association American we patients. help decisions the make the their

devices spectrometers MD Thermo three in portfolio the Altis The and sensitivity a These instruments clinical HPLC. and help labs and TSQ of USFDA-Class new X Vanquish regulated Quantis systems. includes Our meet for throughput now Scientific goals customers medical their environment. and MD mass

our greater new increasingly Krios obtain Cryo-EM high with to applications. makes unveiled reliability. Microanalysis & Krios and images a protein for GX instrument throughput The smaller conference platform and possible it structural structures biology Microscopy during in resolution Second, generation we of

structural features the market operate experienced performance adding easier it and by This to for instrument expands and new makes both new that biology users.

lab. into cutting-edge accessible base. the broader the customer a size, its to In technology Krios addition, make fits with standardized more will GX These benefits a compact

Science had let product our exciting a highlight also couple. Solutions launches me new segment, We Life in

treatment. our antibiotic the about our quarter and A the been better infections leveraging it in genetic have detection We system, from diagnostics. molecular PCR improves deep diagnosis our sciences of to to expand expertise good was example real-time offering pathogen leads respiratory decisions for

demand Automation from System. bioreactors, meet Discovery up TruBio they connects Thermo efficiency solution help trials as customers to and launched workflow and commercialization. to clinical transfer data research software increasing scale and This to easily finally, we accelerate move called for scalable controllers, bioproduction, into Scientific and more bioreactor greater And a

second the industry-leading the our to to QX, in our by growth growth emerging growth our strong high we XX% to scale China. capitalize and on these element strategy, growth. continue We in regions Turning drive markets, presence in of leveraging performance reported led in

many government perfectly China's industry us. with that the plan five-year in Our is create for to continues aligned and opportunities priorities

outlook very Our to and invest continue our ourselves the best from serve we competition. remains to distance customers and positive there

the industry in expanded QX, in China. clinical biopharmaceutical services of pharma the we from Suzhou, to trials conducted we number example, In our being enhanced For in serve to our studies China. support biosciences capabilities capabilities growing growing

offering will services quality packaging new and region the successfully have time. clinical provide these further growing patients in primary This the strengthens some undergoing serving facility pharma secondary and trials. solutions biotech high been ultimately quite our It where we and are customers industry pharma for for who

by the China pharma continued an prospects see innovation exciting we locally, driven formation As industry our encourages of for growth.

clinical on will network packaging of It's advanced With and Suzhou part this region. in integrated to largest quality, supply investment, an distribution. strategy and Thermo a China, the chain logistics facility in focus our with trials chain clinical create cold become logistics Fisher's

that It In workflow diagnostics translational Thermo and Exploration two scientists Fisher consists opened for laboratories our Biosciences disease a development, solutions showcase demonstrate Customer Shanghai, Center help of to modeling. accelerate we complete research. immuno-oncology disease and

position the center for for continue gain needs application Chinese key product customized areas and to enhance be in focus Government Life a sciences hands-on serve healthcare customers as these the This technical capabilities will of hub our there. serving to experience, and new strong customers already training. development our and

The of value customer unique element our our is third growth strategy proposition.

gain excellent and value in it's with capabilities proposition clear that puts resonating our leading to customers. Our depth share and position scale is of well us an our

and To highlights capabilities I position that to deployment future three terms mentioned acquisition I developments, cover from of for participated our But quarter capital in. Company the the organically of continue we organic my inorganically. will increase quarter update. I in growth, our both

Louis, announced the GMP facility team business, last in to batch St recall, the was completed. chance our spring. In the the our since had we pharma expansion biologics services and that expansion I major visited I recognize for you completing a site first may recently Missouri, of the

in breaking an largest showcase CDMO is to our based capacity from site accomplishment Fisher The facility. ground biologics support Thermo platform, of St. biologics now single-use shipping workflows. a XX a months which our and Louis This for production network. impressive the bioreactors Going technologies to greatly increased in automated is product America global on bioproduction single-use has expansion North is

goal The require on to virtual and and to is QX. extensive production the Greenville, had opportunity facility train our and sterile This new also services the injectable of which who center I pharma for work North with Carolina's effectively more equipped complex to are reality lines, colleagues training training. augmented center technologies. in opening innovative onboard go is

cutting-edge ourselves operators and by proficiency These great other not efficiency. of example how time, a benefit the quality tools only required is invest from level capabilities. customers we to give much increasing This our less a also but in internal and organically, of differentiate customer's CDMOs own

West transplant are and Last, was meet of from great providing needs by at having and patients diagnostic grand excellence and this about capabilities and that match customers firsthand manufacturing we serve. effectively of We diagnostics brought our our they their effectively I site It center the Hills, the transplant new distribution patients impact opening families recipients. to research, to donors in our of more the attended hear tools transplant the together California.

you an I'm to on deployment now give our activities. capital going update

which shareholders. execute returning strategy, successfully to as strategic capital continue a our We M&A our to you is of disciplined and know combination

vector In part integration Brammer start QX. is Bio. a Thermo on going good the as of terms start an very off CDMO is with well in This acquisition of that me The and our we business a Fisher. let update is viral to M&A, of acquired

brings are businesses product benefiting deep from gene Brammer that already market therapy Bio expertise the Company. to the our serving Our

quarter-end. We the also right of site completed Ireland, GlaxoSmithKline Cork, after in acquisition our

Parkinson's. ingredients treat is to that our to very API depression capacity are used pleased site XXX network produces including to active court This or we customer Thermo site Fisher. APIs are diseases cancers, demand support childhood colleagues to pharmaceutical and to and new The welcome

for development forward look excited leveraging and production. site on for about to demand capitalize growing API world-class and the are prospects facility the to We this

disciplined in to return very million continues pipeline $XXX we stock QX, in be addition a capital. just to M&A our our we on capital remain active of perspective, forward, of and quarter-end. our stewards Looking repurchased after From dividend

on One capital -end, refinanced comment final deployment. $X.X debt. we billion of quarter After

and further very allowed attractive record Company us refinancing scale to Our our our value. of financial track complete strengthen debt shareholder and unique to portfolio a create

our like a level. guidance review XXXX With would to at high that I

The full-year. As is both increase performance on our the we operational raising and the you are our saw guidance our earnings press also QX activities. strong and benefits release, based revenue of primarily refinancing for our

to revenue our are in new result would which revenue to to XXXX. over We raising growth $XX.XX a $XX.XX of billion X% billion, X% range

In growth year-over-year. which are of to adjusted $XX.XX a represents to to XX% terms XX% of range our raising our we guidance EPS, new $XX.XX,

takeaways So to shareholders. to for launched well and we execute our new summarize and to delivered growth and capital revenue value We performance. our our value continue our also continue our capabilities to create customer customers we disciplined earnings strategy products momentum to our deployment key executed from enhance QX, our and proposition very excellent expanded and

the With CFO, over to that, turn our Stephen I Williamson. will call

Stephen?

Stephen Williamson

for of our and will reviewing XXXX full-year overview and by color through conclude total third updated everyone. Company, four by the morning begin then business our I Mark, segments good taking Thanks, results provide our an quarter on guidance. you

the versus Before out quarter financial I third get a of time me in high provide the of let our last details view our level earnings how expectations call July. the at played of performance, into our

and As more a X% we per in very press adjusted X% assumed earnings in in quarter growth our with you growth prior our in XX% increase QX guidance. release, than was share. we $XX The approximately saw strong delivered organic million organic would

from operational strong had assumed driven environment. at midpoint previous EPS and was we guidance. less $X.XX our was This FX adverse a by higher $X.XX $X.XX of performance than from the Adjusted

Company. for quarter the excellent another So

me $X.XX. financial the performance. In quarter. QX, more last year. Now the XX% EPS up provide total let to detail Starting in from with quarter QX we on was grew our adjusted GAAP Company by X% $X.XX EPS

reported revenue year-over-year. X% On the our top-line, grew

X% growth, components The organic acquisitions, our and X% the headwind X% Pathology divestiture included business. exchange, increase of QX X% foreign decrease from contribution of our Anatomical from revenue to reported a due of

XX%, high the and in Turning rest growing the North grew the high our by single-digits, to grew growth grew also in world Europe geography, America single-digits, grew Asia-Pacific mid-single China in single-digits. of with at in the digits, low the

adjusted QX We and operating and by and basis in income increased offset was Looking pull X% delivered from strategic volume at up adjusted operating part points business QX XX productivity XX%, margin our through mix. performance, operational strong investments unfavorable XXXX.

foreign was on no X% adjusted The QX on in was adjusted and material expansion there income, just from revenue but in from adjusted headwind exchange margin FX operating over operating quarter. or the impact EPS

of reminder, EPS. completed the divestiture income of with last adjusted basis and adjusted quarter. Anatomical margin million of XX business $XX The revenue, in operating of impact QX the of sale As was a points on a over adjusted operating Pathology $XX reduction million and just the $X.XX

by the In QX offset strong details XX.X%, mix. of total investments down on was points business unfavorable XX was the Moving to productivity P&L, the margin gross up strategic adjusted year. in basis from and the quarter, prior Company

Adjusted points versus a of XX revenue, revenue revenue, XXXX. R&D our percent quarter at the of X.X%. came of was improvement basis Total QX in in SG&A was R&D XX.X% manufacturing QX expense of an X.X% as in

Looking approximately Adjusted million $XX than other at net foreign driven income from the income which year, QX million, the interest higher of our primarily due is non-operating QX quarter quarter, below to debt for was changes XXXX, our million, and by expense $XXX net expense line in primarily the reduction. in exchange. was a down last $XX results

lower shares option as rate was QX year-over-year which QX average basis is a million the Our million, XXXX. were mainly in QX buybacks, by $XXX result which points dilution. adjusted offset was XX.X% $X share of tax diluted XX partially lower

quarter billion to and $XXX of of $X.X We flow sheet, cash free nine-months Turning from and cash flow deducting was expenditures cash balance flow investments. in operations billion capital $X.X cash the the $X.X million. after billion year for the first ended continuing with the and with net

XXXX we shares, In our total returned billion. bringing $XX repurchased million QX, shareholders we trade repurchases dividends. of to XXX in Early $XXX through million our for QX, shares our and of to million $X.X

Now turning portfolio. our debt to

$X $XX.X reduced flow debt strong total cash billion year-to-date our billion QX, by During to a driven generation.

times quarter. total ratio quarter X.X from the leverage was the of end three at EBITDA, to down last end at adjusted debt Our the times of

XX in current debt is which In we of billion completed and addition, new earlier, cost interest has an years cost our it debt of $X.X P&L maturity debt. replaced. mentioned as Mark all The that recently refinancing average average the of the adjusted X.XX%, an of half

And represents Company increased quarter total last interest year. of from XXX million saving This my points wrapping QX an our up of $XX to approximately up on per adjusted ROIC for our performance, XX.X%, adjusted P&L. basis comments

continue to We investment. on returns excellent drive

an In provide businesses. performance saw segments segments, will reported starting good our business the and third growth growth color the biosciences some with with bioproduction both QX the I across Science led quarter four We Now our on XX%. Solutions Segment. you Life by organic of revenue of very

XX% very increased strategic XX.X%, volume XXX adjusted investments. X%. In led In year-over-year. strong up the drove X% Life segment, points is reported revenue chroma basis by through quarter, in and Solutions spec operating revenue Growth by in QX organic growth partially which increased income Time we Instruments QX adjusted mass and was the offset was Analytical pull business. operating margin segment and was in the the

XX%, was points very up Instruments offset a partially In adjusted This mix strategic operating quarter, increased productivity. business year-over-year. we the saw adjusted investments. by XXX QX and Analytical margin unfavorable and income in was X% operating basis strong

in segment segment transplant the segment growth that good organic include QX, business quarter. divested to reminder, this to revenue We X%. Anatomical the Specialty the growth as revenue In the a by Segment, last had that was declined across we led this X%, immunodiagnostics. total the Turning Diagnostics is diagnostics used Pathology and

productivity, the impact was prior-year unfavorable Pathology the business. volume year-over-year. the through due was the basis points income and business XX from points an offset partially flat a in was basis which sale XX.X%, operating investments, pull the mix Adjusted we margin up strong to Adjusted Anatomical by impact a X% of strategic In XX quarter, operating divestiture. saw from

segment, prior-year. quarter, operating basis XX.X%, by increased leverage, was the business business. adjusted growth segment the is and X% we segment We and across in both was and saw revenue quarter this margin organic points our and the pharma XX Adjusted operating income productivity Products which offset In and volume Laboratory X%. Finally, lower strong saw services this in reported is than by strong investments growth Services strategic mix. led which unfavorable

I move like to Now would to our updated guidance. XXXX on full-year

mentioned adjusted both release, and saw you revenue and EPS press are raising we earlier, guidance. our as Marc our As in

details. the range through of our $XX with you midpoint by revenue and will guidance tightening increase the the we elements. million revenue, in walk consists three $XX midpoint of raising I The $XX million. me Let million are begin by the

increase million which performance full-year and in QX outlook in X%. year, assumptions growth for growth our the increases $XX organic strong a This to no outlook our First, our for the organic QX. for change reflects the

second is our of FX is API previous the Ireland facility. of a the addition Cork, to guidance, million an more element $XX $XX revenue reflect the element The acquisition million, versus adverse third and of

adjusted share. Turning to earnings per

strong and increase $X.XX midpoint adjusted the to of four increasing consists by elements, $X.XX by interest of EPS increase expense. to The $X.XX range lower the are We guidance QX $X.XX tightening our reflect $X.XX. operational increase the from midpoint performance; the a

refinancing; of adverse reduction and FX more the share QX, $X.XX for reflect result we to $X.XX a As versus increase of environment early guidance. recent in benefit a our repurchases a a debt previous undertook our the account to

of it a benefit $X.XX to to revenue $X.XX in you to give relative and QX, foreign billion represent in the QX is would $XX.XX more reduction our exchange. X% X% our bit to change, a prior reported is detail billion, guidance of organic XXXX range up, XXXX guidance which comprised versus on growth sum a reduction this me now $XX.XX growth. Let $X.XX X% a To

our expected $XX.XX EPS to XX basis be for XX% to growth adjusted points and Adjusted guidance to now of margin about And is operating now expansion XXXX. XX will versus XX% points. range of XXXX basis a XX.X% in of which $XX.XX is represent which result margin

the guidance a revenue, of FX mix last below income on our million million impact A line. few adverse revised operating $XX $XX XXXX the adverse FX, full-year Starting positive of guidance. the details rate from net impact and since million changes an the adjusted with a had impact $XX behind

So now adjusted impact of a will for the XX or revenue about basis $XXX full-year we FX $X.XX negative our X%, EPS. in that or on X.X% assume million have margin points and of approximately

Next, over which $X.XX gross points XX and be adjusted margin just guidance. million, expect of continue the we impact approximately from of year-over-year no to impact previous is EPS, to tariffs $XX approximately basis our change

will debt the billion. below are Moving year-end now we approximately $XX.X be line, assuming

Our the than will approximately income about be $XX the are debt $XX assuming net our is QX. million will other FX down from July million, prior refinancing. higher recent of net in reflecting $XX of interest benefit $XXX expense we And reflecting be million additional realized which non-operating about guidance our million, benefit guidance

We continue adjusted guidance. our from the be rate previous unchanged to XXXX tax XX%, to expect

will change We from be billion, no million Free capital for $XXX are continuing million expected and to flow previous to cash guidance. expenditures approximately is $X.X assume be year. between the net $XXX

we previous $XXX buybacks. year does does million guidance $XXX share of guidance recently this include and million buybacks shareholders estimate reflecting return $X future or previous will a the dividends, to this diluted any additional now guidance not divestitures. lower any our than shares completed assume our through about change acquisitions and approximately full-year not average be share My approximately from year no million, assume capital our We

in the summary, In performance the of excellent first delivered and continue year half the we achieved quarter. an we strong third

very well positioned We the for goals achieve our are to year.

back With the that, over I call Ken. will turn to

Kenneth Apicerno

are Operator, Q&A. up we open Stephen. it to Thanks, for ready

Operator

first from Tycho question Peterson the comes ahead with JP [Operator of Instructions] line please. our Morgan. And Go

open. Your line is

Tycho Peterson

I'm there quarter. deterioration on in congrats slightly any is I conservatism. the to with it prudent the guide, that factoring comp Hi, you want with easier quarter macro are the some thanks, X% kind just sequentially. there is the is wondering, of guidance, fourth or start just and maybe

Marc Casper

and question. pattern is for all normal the with at quarter, When back year look thanks identical year the budget Tycho, remains subsequent the assumption the what which it to the the you guidance started of original in to the end spending. for assuming we part fourth January

average So, as or and that, and a spend, the year-end quarter. XXXX, in visibility to get and above last of years couple so the XXXX you late don't very reminder, we had strong

what and fantastic we guidance year-end, has So, year are the delivered plays assumed the positions is our we in that that have a convention out, normal that been will is our way year.

get an If flush, better even strong budget very performance. terms in you be year it another of from finish then will

thinking giving So that and the a to change viewpoint. about not macro are anything negative we it a in us seeing is are is conservative environment like we how or that from QX

Tycho Peterson

for of on obviously did Okay. some over around And one particular capacity biosimilars. in potential there. biomanufacturing, the follow-up great numbers from concerns yesterday about you putting peers then hear are your We up

curious, have industry your if and I'm points there separately, if now. some obviously Spark. Sarepta Brammer. But then comment gene there that as and robust still around for the there the think data And been denial is thoughts mixed right very just the could I'm we about you capacity cell around So on on curious pipeline therapy [indiscernible]

If comment that? Thanks. you on could

Marc Casper

Yes, so Tycho thanks for question. the

is is high great. Right. performing really So at a our business bioproduction And it level. doing very

great Our where media customers had in a and the we cell single positions we technologies are leader. the quarter. industry strong appreciate have culture use We

is that So continuing.

relationships these across very what gives we our have seeing a and see is have have other lines, obviously we you how business, market, the biologic the We pharmaceutical very of terms CDMO which have industry. one insight, we and we biotech activity. pipeline you so lines. because are we a robust the And best all gives bioproduction which the have In then we of deep companies

the what future holds. good about feel we So

therapy, competitive going around and see to businesses are in excited promise In but market. are the as young gene business as our therapy position, very gene both continues are these of volatility, we about and individual and that cell and be strong Company pharma serving you product services our to our terms well industry, therapy very cell

good the So about Thanks for we outlook Tycho questions. there. feel the

Tycho Peterson

Okay. you. Thank

Operator

from Jack line Barclays. please. of Go ahead the Meehan comes question with next Your

line open. Your is

Jack Meehan

Thank morning. to noise, you. what the growth region, Good I obviously come wanted which out. been little more China with around are we right a for, has was start bit XX% looking but so

just as walk you So are you there weaker, you any just some are what I where was wondering us looked are across be that that doing are the businesses. through concerns the areas great? it, areas that there any of or areas doing Are if better, would have any

Marc Casper

good and the morning thanks question. Jack, for

In we right. look very have of I how China, at performing another When terms excellent been strong. quarter,

the five-year enable capabilities we plan, our is customers around that to the which their building expansion protection, government with system, an be the priorities we aligned market bring industry. and Our Chinese pharma the well to environmental of value incredibly healthcare industry continues innovative so the

are things positioned see in our terms Fisher, even you technologies benefit we industry us results. our have performance leader, our as our very unique and Thermo industry position front in that of that China the in across Those all better competitive that and a

of years. in on of what similar what seen of last China, continue to couple very, be conditions the going in is really to terms details we the very In have

last meaning very finish, globally. the a also end very, in the had year our we reminder, in year strong that play in comparisons industrial the business second true businesses industrial a as half And China, of

you as So you that we in difficult But have markets. results comparison there little in see well. China see that across a and a industrial bit the end

are mid-teens on deliver the for So the growth growth to XX%, year. very we strong track

where will we So it. see

Jack Meehan

products Great. And Analytical seem the , terms between the us walk and seeing get just in through just Cryo Semi bit, dynamics of the timing the of versus finally didn't even I the you then terms moderate adjust in share a in Thanks. the be for underlying of to would little microscopy a if some follow-up market, hear could you versus you how certain are threading as gain macro needle are helpful. there on you growth terms then called of what Instruments electron business out,

Marc Casper

Yes.

Jack, where year a the and terms very with most good and it's analysis. our have That strong electron second in terms microscopy had of most we of chemical So Instruments. last a exposure segment industrial in exposure Analytical industrial question. half in we is our business

expected amazing more we comps been of in against expected to that year second the challenging have performance half have we last because the So our and since the we -- the growth businesses articulating challenging the have muted performance we year. begin industrial the

a So that is the think at level. to kind I of the the good spec that, below detail about more continues perform mass business context. When and chrome

in others are have Obviously, companies. not reported our industry we yet, first of major the

the was feel another on know that we are others, based we very customer QX feedback quarter share of versus gains results exactly excellent have, but to what it's hard our So there. good

next be So, that the so. validated in week will or

for In long-term our is the terms business microscopy, outlook electron of outstanding.

applications. our the from in materials materials battery Sciences We have great interest applications both Life development, through advanced semiconductor, science ranging

to think where business mid prospects continues term. long-term I growth about when is over the are to high long single-digit So that business be

feel we position we about So how good and Analytical our in are Instruments performing.

Operator

Your Kumar ahead next comes question Vijay the from Go ISI. from Evercore of line please.

open. is line Your

Vijay Kumar

here up maybe spring the Marc bioproduction I maybe market about think growth we end the commentary you LPS, an biopharma, may just on is a I back seeing Life quarter-on-quarter both versus also Thanks accelerating, markets, how a my much be think your services stack, helpful be of business double-stack would markets, here. are outperforming this in really because question end out Thermo you strong, and parse point. acceleration mentioned but scale - to but of business, taking what on question maybe can going is really starting just congrats in non-services this the what for nice Science that those strong, and

Marc Casper

Sure.

So the question. Vijay thanks for

number all, of growth on another we how what a setback we seen are consistent quarter of quarters. for of doing First biotech have a is pharma, double-digit from now

are have that and do at market their The value position really same all and well, truly to markets them of gaining we the unique their that growing are businesses productivity faster unique we helps our good, did proposition industry our customer but innovation point that and and accelerate a and the than them is is that because drive share, competitive our clearly set. understand serving customers help

good of good. continues biotech as bioproduction high feel pharma other very at perform about highlighted Services. the to some When very, earlier I also, very continues So Lab I be Products we segments and that to level a about and think so

think I that across They our products business. growth. there, about solid quarters business when the our channel pharma includes good which very all of had and services And our businesses, all with lab businesses

nothing particularly between had quarters all businesses, they on top-line. those strong differentiated the So

Vijay Kumar

Thanks. big have maybe over one When been phenomenal. question, capital it then comes you to guys picture deployment the And years.

is look funnel Just appetite sector. environment the valuations is given the looking about talk across you when Maybe, rate how at a where the M&A. and for

Marc Casper

right deployment. very it transactions customers, the a have So, to been it of thanks. creates we and have and doing No, Company’s strategic active. value. really meaningful disciplined successful about be funnel, very much in active ultimately way that continues long-term our we is very we process is position, we strengthening very valued have the shareholder where the by and right And terms capital think a is

And us right. we always is feel about disciplined, be when look always will good that, at we key I I are for prospects the the what and been very the And pipeline, disciplined there. have

the So, things. will do right we

And that, what right. And average year financial positions have of new our gives flexibility. a years when duration an sheet strengthening It XX that I think With on well. debt. long balance year, for term, great costs us the the the tremendous in us interest doing getting of about this terms

have selling And in at portfolio, the mid-sized bolt-on same small of business. the done acquisition, point, have we a Brammer, cleaned which one up off done we Cork as Pathology was well, few Anatomical aspect and deals one our the

well I year there, have very we about looks M&A the pipeline So, feel like. solid so what a as capital returned and great

Operator

open. your Go of please, from the comes question Derik is Bank Merrill next Lynch. Bruin of Your from line America, ahead De line

Derik De Bruin

you. for question a have I Stephen,

So, I get a that. "Your Patheon, the about you bought lower gross I call margin and your have came mean, BDPS" like every conversation ever be guys margin have seems street numbers other I you a Thermo gross mis-modeling number. and how quarter that, since in to to

some just this. with of I goes the so on this. a question be on how ultimately dynamics everything line of to like like on to how any like people it there look have sort Can model year-over-year what And it's margin we of the sort number consistently this the to and and And about think plax just it's how mis-modeling and you walk quarter quarter, we it. seems should sort that gross margin think mix the that. there of one at every margin this, is, or how gross expansion sort on Because is like through right on debate

Stephen Williamson

for Yes, question. Derik. Thanks the

So long we a will take back. look

So, yes, so significantly average Patheon the gross on business lower margins for is Company. with a the scale

XX-months, still Pharma over you the that on back margins, saw Services in pressure business. So business performance for that line to on our good of the a into the some the four quarters anniversary numbers a reported gross that year is

still been the profit there then Company, fastest. but that revenues to businesses mix serve gross the our below that, margin been of decent businesses have growing in such the And lower is the lower cost margin

well, then services also So well. channel bio-production then and and as the pharma is business growing very

of a good very margins, still dollars. is but operating terms adjusted pressure reported continued generation of on in that income So

revenue we So seeing future that growth. Services our fairly Pharma dynamic into out. play are recently significantly for investing business And

we And one a elements. also basis. Anatomical will reported see the margins plus the then on that gross couple that So the selling this over Business, Company’s bit and on a little is, you it is of Pathology pressure next other are the quarter,

to modeling not So Well, going leverage. that it's some when significant, the terms of get think I expect coming Company forward. expansion I about SG&A but margins, out really of gross in margin benefit and

long-term the on the outlook the to that years. of the next the strong With driving top-line revenue operating really Company three going the expansion is for for in growth overall be terms margin

Derik De Bruin

how track And revenue that the Great, the the - thanks the drag gross and much Can remind How What incremental drag in growth very that. like mentioned on us for on of Anatomical hit margin? you sort on bit like strong. organic on the a little Pathology clarifying sort I'm margin. of was much where quarter, you that out, had that sale. quarter, on you diagnostics gains second plus And how was of from business. Anatomical was of growth X% the of in the getting just that in some out, delays coming the volume? that

Stephen Williamson

strong really in growth terms momentum, business, Specialty immuno-diagnostics, our strong healthcare transplant, So, of our performance very in in we right and strong in have performance and of Diagnostics in in healthcare Derik, broad-based performance channel. excellent really the terms in and market the diagnostics

divestiture Anatomical impact a growing actually a Pathology, slower growth business, was of performance. on the So which the had organic minimal

Marc Casper

of delayed tailwinds there. the the net from revenue not significant was QX terms terms basis. a And of when you shipments look offset in overall on impact in a But that

Derik De Bruin

about Since is which Great. that really you I while. And mentioned a can transplant if continue. haven't diagnostics, for talked

talk people As Lambda years a you I of market. was ago now going has worried ago that we that a opening back, sort coming waked just facilities. because the sequencing to were when debate several was that, how see Can next-gen people. obviously very remember had And with you from I I'm there One think of was time years to new get are into about curious expanded. couple a that

Marc Casper

clinicians organ we right. of we recipients globally, help terms in we match in and terms transplant so right health, is Yes, incredibly of which capabilities diagnostics important or acceptance donors with that transplant healthcare the community serve help rejection, monitor

that do but been work make I the truly opportunity. inspirational do, of decision process an doctors the medical on love part the But what business role recognize It's performed donors. that And to play, good growth. profitable, highly I the that critical So there. recipients the opportunity it's those to talk has the the decisions, to the with we laboratorians match patients well.

we an that set new of our West had Hills, August capabilities. amazing in in opportunity opened is which facility up when I

And of the we was experience. advantage really have. have an competitive attending, people highlights awesome it We hundreds

a customer is bright wasn't the there leader Right, but didn't investing future. for leave there this okay, a saying, industry

our next-gen transplant sequencing We way in the diagnostics. have by workflows

So have we well made very and continue be that performance we as there. transition strong to

Derik De Bruin

just I advantage will the follow-up. of on one call to Since here. I then, take And being

of your with have the the talk services one market. of competitors business been It's of your third-party really and and sort areas has Services Lab just, making of lot a You are visibility. a like we going those big of know Can into is we it. dynamics about on Unity what push sort one you industry, and

with trying some the just the of some the, of I'm that from so of and trends commentary reconcile sort with, of other competitors. to And some

Marc Casper

our well, number colleagues performing level growing, customer our laboratories so how Company with our at level. that they performing of our with a a [indiscernible] a it's getting to Probably It's operate a continues higher they're business the of regions lot ensure good at probably up a large great we wind site customers, in experiences customer of terms building making their at in effectiveness around range, good average. products. And perform and grew and somewhere sure to good it's working .

Operator

open. Go line of from line Doug next question & please, the Your ahead Cowen is your comes Company. with Schenkel

Doug Schenkel

few XXXX year-end through you. Good morning through then a And QX a and I of about couple talk run talk to clean-ups. want and to dynamics. just Europe thank

in we quarter high you anything impressive different Europe Can revenue of is had cadence? there I segment Europe. heard pretty was your surprising performance where have Europe, the growth areas. single-digit monthly and by starting lot performance Based would is detail from in a of and terms on high one growth also on things others, more a share provide on if comp. most you in of So what argue, strength and robust read especially surprising, in single-digit interesting bit given a your

Marc Casper

Yes.

question. thanks Doug, for the So

right. been You know, interesting, it's

quite popular you about If Europe, of the have for some this sort you time. read press

this view, forth. You is sort everything of bleak slow so very have right and

If over look at last of number our then you the years. performance

in strong. performance is very Europe Our

So, resonates, very a big there positioned that right, that we well is serve. is because there presence pharmaceutical our value to are proposition industry

reflects diagnostics team, in growth and by have we We high-single the high-end instrumentation market, very performance our been The have Europe. and strong growth good the is is performing business of well. strong digit the customers, delivering presence serving valued

did European and spent is team we our leadership our excellent. when the with and time be continue in our myself Europe at our good, with So team end conditions of to members share market Company we gain and where the leadership commercial and quarter reviews serve the of momentum

well pleased done to out as I jumped really was nothing by team. me particularly the being So surprising. just the job with

Doug Schenkel

Okay, that is great.

you about if the want was or on not anything On by down segment clean-ups, $XX confirm would the to I and just in storage for between now is to the recapturing break quarter impact data second lost of million, revenue to recapture comment that that and Now more the whether so, related and year-end. there outage.

Stephen Williamson

Thanks. Doug. Yes,

from we quarter customers are as last ready in QX. at were approximately and call then the average of to QX the the shipped $XX delayed of orders the to So, were by shifted on system that These outlined QX. early shift end million revenue to right

across So basically that line. the is

Doug Schenkel

was up on clean other the then And Okay. Bioprocessing.

is we wondering quarter, leads might conclude whether to the our XX% right XX% to grown which in Just that are if have math right, you in not you could the comment us on or neighborhood?

Marc Casper

the Yes, right in neighborhood, you are

Doug Schenkel

outlook ahead just looking year-end Alright. and just flush. then of Okay good flush okay, how has questions then is a is first guess there has years last been I one the and neighborhood. How this it been, a There the a And the is, important of you couple budget budget context - been it's . guidance. the in of focus on important year's for to few lots

first budget So that flush. one on is the

of the XXXX, and terms than planning and all XXXX into question uncertainty your think a then the level your there, do higher and how kind impact budgeting your you, is if backdrop macro in you later that just complete for likely usual out planning heading is given customers are visibility the and does second The Marc. to of third so,

were capital companies. into companies we emerging XX year to the but where of relatively if biotech about were an also and there higher-growth smaller for pharmaceutical ago, about the for heading by years heightened XX concerns environment extension then regardless size concerns and availability election of

ago half about and moderation a to that would of a end possibility spending say a we a market. be fair decade for it's the that think decade concerned I and

really they'd materialize dynamics ahead market these end just the biopharma at your that today complexion those than that We were it be XX dynamics has they can where . to Thermo Thank the last changed over that less looking end overall or to fair say of may ago. nature years for say you XXXX, facing exposure is some you problematic of be the XX enough market decade, of to

Marc Casper

Sure, great question.

one feel I the uncertainty this I think , here, had and call. the two normal or Let me doesn't is is actually a more when last first at back that preparation of over later decades in shot lot actually of the for challenges any a of doubt that a macro right. take planning And there something it customers really earnings then level environment. do noise,

administration is a remember big publicity discussing lot sit sequestration, risk changes dramatic there say, Science I all very is and things issues that I FX oriented, but - terrorism have I is great. of when in yes, there picture an discussing think when and and these and the about we

very doing the good The and economy industry around well. our pretty world is is

think going to industry. be terms think I across pretty the I planning, in of the about normal when process it's So

if In terms Company biotech is our mix be you excellent, you and might right. all it those the has things, a changed, science of change know, view and end market strong, funding and of, [indiscernible], have to continues the

think been the decade with clinical our ago, and of balance and and biotech research pharma equation, If have in would today trials, more a of more you production. exposure about the have a you on development capabilities, purely side

different stickier movement. the of is latter mix terms the stage So, typically in in that is

normal gives you point two about from two view roughly year be of between at hard in that of terms normal view our scientific in points, a of strong that, a of and growth magnitude little growth to difference go it, the meaning so in and full-year organic to quarter, additional bit, you but then best half year the terms the have forth, a and between that And strong. probably points least in it's off a something difference spending of the if represents could and it of strong a that budget growth, normal for the of

Stephen Williamson

[indiscernible] thinking It's you and through planning Yes planning about are flexible about to up how in sure and of that an environment. that and operating you environment pretty kind making change being it's of about iterative things rapidly. these with terms about date

are more becoming to more accordingly. environment companies used So, and that and operate

Marc Casper

for ready are next the question. We

Operator

question Wolfe next of from Beuchaw with comes ahead And the Steve is line your Research. line open. your Go please,

Steve Beuchaw

then over time for growth we actually investments? for the and good think capital or for the investments How CDMO do CDMO in broadly in Stephen, up see morning, capacity level new for thanks I question in and reasons we one obviously with a years, Stephen, time modeling good Marc. for next should Hi, up those deployment CapEx that have then this will here. capacity. we you over broader I guys about follow have at few are stable stepped

Stephen Williamson

Steve, great question.

about If the to want pharma business. services think you

great growth biotech long-term large organic with that set and got pharma customers have customers. to opportunities and more both we capture the have biotech We

long-term. right adding and that to help So we we are and continue the that recognize to the fuel capabilities growth for capacity

level to be we business growth. that to opportunities But we will heightened organic CapEx that get of maintain will out kind there our going single-digit and the year growth high themselves, will think you to business And add putting maintain future that business to returns pans if to of us gets I'm from appropriately see to high links slightly year of prospects being that great, that to great in see how So level that great income these and about great really, and mid . next the method of end forward. and customer at investments that are unfold this able and CapEx,

Marc Casper

to as we huge one And next at of another did took of kind costs. just a we earnings. benefit is line. level year, Right. million add $XX million the the would I have interest think I QX lower in - will our thing bottom it $XX refinancing One and which we savings the really about off, benefit from

se continue services, share to have in a likely more half reinvest but to that momentum pharma prospects will given growth not per in momentum. We our little of our than just amazing we accelerate

see So continued reinvest us some I future will fueling think for Company. savings the you likely those of amazing into

Steve Beuchaw

but so wonder let's optimism very lot been But a space or Thanks about good last, talk all, at not on then, have downstream those say view if there Very, trend it. grower, Got historically space. again in more talk the over if gainer of bunch. some good and Marc, competitive growth your you how, And a evolve is could you know share entered that about trajectory trends I a you've others the in the I nine-months proteomics been has the there. there for minute. where noise a for and proteomics. Can about helpful. this XXXX just reason of a

Marc Casper

our the the is franchise in QX, at very Orbitrap Yes, business, American product very we of well. I had performing interest. customer strong look And launches, Spectrometry when it ASI Society Mass

good always is We positioned but order performing are well well competition, there we very drive to very to have had shipments, growth. and continue

looks is positioned now revolution, that really good. the proteomics level and to good of continue you in It and you business. where genomics are and we our if very have huge leader of a funding have proteomics growth Funding right well about, to the in is to is, drive part is think Right. industry

Steve Beuchaw

here. color all Okay, the I appreciate really

Marc Casper

Operator, time Yes. more. have one Steve. we just Thanks for

Operator

open. ahead comes your line with of the Brandon Jefferies. question last line your please, And from Couillard is Go

Brandon Couillard

Marc, where on in synergy good and pull through the an core just revenue could speak of you share curious if terms asset? you update third Patheon about stand perhaps growth quarter that the morning. to Thanks, from in

Marc Casper

complete. exceeded track. cost our PPI synergies we driven from Yes, System excellent integration the at is an The is so on performing Business level, right the revenue synergies, impact really by excellent business

enough, interestingly future funnel of wins, revenue. the which is And

sold You can and revenue are really see expansions is acquired our synergies, network have driven right. it basically announcing across in facility. by Cork the we we out that that our API number of We the network

interest is Thermo [indiscernible] performance You Fisher's business services,. pharma about of the grew reputation our from how reflection The strong of the saw performance terms a and excellent us really customer Company quarter. is of the average announce in biologics just and expansion networks our because and in of and sterile that

Brandon Couillard

full just Stephen, Thanks. pricing can year? in net you've quarter, for baked for one what the you the and last in And share

Stephen Williamson

continue net to be a It's good. pricing

the across line with X.X% under how that just be Company we for So year. is performing in would and this

So of however, expect well. offsetting and are continue, the impact a good doing job tariff pricing of to that some of as being disciplined we

Brandon Couillard

Thanks. Okay,

Stephen Williamson

Thanks Brandon.

Marc Casper

a wrap position up are strong let behind year. really me a here, with So nine-months achieve us, we in to another great excellent

look We for support Thanks XXXX. As always you thank everyone. forward Thermo Fisher to you of early your in Scientific. updating

Operator

conference. for you your today’s participation. do thank concludes This We

now may disconnect. You

Thermo Fisher Scientific (TMO) 23 Oct 192019 Q3 Earnings call transcript